LEADER 05388nam 2200649Ia 450 001 9910146239203321 005 20170814190048.0 010 $a1-280-52054-X 010 $a9786610520541 010 $a3-527-60545-2 010 $a3-527-60152-X 035 $a(CKB)1000000000019354 035 $a(EBL)481598 035 $a(OCoLC)68940976 035 $a(SSID)ssj0000229673 035 $a(PQKBManifestationID)11175951 035 $a(PQKBTitleCode)TC0000229673 035 $a(PQKBWorkID)10168308 035 $a(PQKB)11226454 035 $a(MiAaPQ)EBC481598 035 $a(EXLCZ)991000000000019354 100 $a20030804d2003 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aProteomic and genomic analysis of cardiovascular disease$b[electronic resource] /$fedited by Jennifer E. Van Eyk and Michael J. Dunn 210 $aWeinheim $c[Cambridge] $cWiley-VCH$dc2003 215 $a1 online resource (426 p.) 300 $aDescription based upon print version of record. 311 $a3-527-30596-3 320 $aIncludes bibliographical references and index. 327 $aProteomic and Genomic Analysis of Cardiovascular Disease; Preface; Contents; List of Contributors; Abbreviations; Section 1 Genomics; 1 Large Scale Expression Profiling in Cardiovascular Disease Using Microarrays: Prospects and Pitfalls; 1.1 DNA Microarray Technologies; 1.1.1 cDNA Microarrays or Oligonucleotide Arrays?; 1.1.2 Designing Meaningful Experiments; 1.2 Computational Analysis of Microarray Data; 1.2.1 Raw Data Analysis; 1.2.2 Comparing Expression Data; 1.2.3 Clustering Algorithms; 1.2.4 Data Sharing; 1.3 Potential Use of this Technology in Understanding Complex Heart Disease 327 $a1.4 Acknowledgements1.5 References; 2 Global Genomic Analyses of Cardiovascular Disease: A Potential Map or Blind Alley?; 2.1 Blindly Searching for Structure-Function; 2.2 The Starting Line: Garbage In - Garbage Out?; 2.3 Is the Mouse a Valid Model for Human-Based Disease Transcriptome Studies?; 2.4 Arrays and Cardiovascular Disease; 2.5 Filtering the Transcriptome: Enhancing the Value; 2.6 Concluding Remarks; 2.7 References; 3 Heart Failure: A Genomics Approach; 3.1 Overview of Heart Failure; 3.2 Pathophysiology of Heart Failure; 3.3 Genomic Approach to Heart Failure; 3.4 Conclusion 327 $a3.5 Acknowledgements3.6 References; 4 Principles of cDNA Microarrays as Applied in Heart Failure Research; 4.1 The Clinical Problem; 4.2 The Need for a New Paradigm; 4.3 The Potential Role of the Microarray; 4.4 Strengths of Microarray Technology; 4.5 Caveats of Using the Microarray Technology; 4.6 Experimental Design; 4.7 Tissue Preparation and Preservation; 4.8 RNA Isolation; 4.9 RNA Amplification; 4.10 Probe Labeling; 4.11 Data Analysis and Bioinformatics; 4.12 Application: New Classification of Disease; 4.13 Application: Pathogenesis of Disease 327 $a4.14 Application: Early Disease Markers and Prognosis4.15 Application: Therapeutic Insights; 4.16 Acknowledgements; 4.17 References; 5 Gene Profiling in the Heart by Subtractive Hybridization; 5.1 Strategies and Limitations of Genome Profiling; 5.1.1 The Biological Problem; 5.1.2 The Model; 5.1.3 The Technological Approach; 5.2 Analyzing Gene Expression by Subtractive Hybridization; 5.2.1 Methodology; 5.2.2 Advantages and Disadvantages; 5.3 Genomics of Myocardial Ischemia; 5.4 Subtractive Hybridization of Myocardial Ischemia; 5.4.1 Myocardial Stunning 327 $a5.4.2 Genomic Profile of Myocardial Stunning5.4.3 Chasing Novel Genes; 5.5 Summary; 5.6 Acknowledgements; 5.7 References; 6 DNA Microarray Gene Profiling: A Tool for the Elucidation of Cardioprotective Genes; 6.1 Introduction; 6.2 Candidates for Cardioprotective Genes and Possible Mechanism(s) of Protection; 6.2.1 Candidate Genes Involved in Cardioprotection; 6.2.2 Potential Mechanisms of Cardioprotection; 6.3 Is There a Common Set of Cardioprotective Genes?; 6.4 Effects of Long-term Activation and Dosage of Cardioprotective Genes; 6.5 Approaches to Identify Genes Involved in Cardioprotection 327 $a6.5.1 Preconditioning 330 $aThis is the very first book to focus on this new approach that will eventually aid in developing new diagnostic markers and therapies for controlling and treating heart disease - the number-one killer in the industrialized world.Divided into two parts, the book describes not only the potentials, but also the limitations of these technologies. The editors, both well known within the scientific community, provide new insights into the biochemical and cellular mechanisms of cardiovascular disease, as well as covering the transition into clinical applications. In so doing, they highlight the v 606 $aCardiovascular system$xDiseases$xGenetic aspects 606 $aProteomics 608 $aElectronic books. 615 0$aCardiovascular system$xDiseases$xGenetic aspects. 615 0$aProteomics. 676 $a572.6 676 $a616.1/042 676 $a616.1042 701 $aVan Eyk$b Jennifer E.$f1959-$0932854 701 $aDunn$b Michael J.$f1936-$0932855 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910146239203321 996 $aProteomic and genomic analysis of cardiovascular disease$92099651 997 $aUNINA